Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jul 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called ruxolitinib on patients with myelofibrosis, a type of blood cancer. The goal is to understand how different health factors might influence the long-term survival of patients who are being treated with this medication. The trial is looking at both new and existing patients who have started ruxolitinib as part of their regular treatment, regardless of whether they are participating in the study.

To be eligible for this study, participants must be at least 18 years old and diagnosed with either primary myelofibrosis or myelofibrosis related to other conditions like essential thrombocythemia or polycythemia vera. Patients need to have had ruxolitinib therapy and must be willing to allow researchers to collect and analyze their health information. There are no specific exclusions, so if you're receiving ruxolitinib and meet the age and diagnosis criteria, you could potentially join the study. Participants can expect to contribute valuable information that may help improve treatment and outcomes for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice.
• • Availability of data on clinical history prior to initiation of Ruxolitinib therapy
• • Obtaining informed consent for data collection and processing
• Exclusion Criteria:
• • None